Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability Between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers

Next Previous
Trial Profile

An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability Between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NDC-002 (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors DR.NOAH Biotech

Most Recent Events

  • 26 Oct 2023 New trial record
  • 02 Aug 2021 According to DR. Noah Biotechs media release, the company submitted an Investigational New Drug (IND) application to the Korea Food and Drug Administration (KFDA) to demonstrate its new phase 1 drug candidate.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top